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Induced pluripotent stem cell-derived neurons from patients promise to fill an important niche
between studies in humans and model organisms in deciphering mechanisms and identifying
therapeutic avenues for neurologic and psychiatric diseases. Recent work begins to tap this poten-
tial and also highlights challenges that must be overcome to be fully realized.The relative ease with which induced pluripotent stem cells
(iPSCs) can now be generated from human somatic cells may
change the way that we study human disease. Nowhere is this
clearer than in the brain. Neurodevelopmental and psychiatric
disorders have been challenging to study in the laboratory, and
despite a large investment, few novel treatments have been
developed in the last decade. One problem has been the lack
of predictive preclinical models that can be used to study the
pathophysiology of a disease, identify therapeutic targets, and
test potential therapies. Though animal models have been
valuable in elucidating disease mechanisms and in providing
insights into the function of specific genes, they have a poor
track record when it comes to translating findings into human
therapeutics (Dragunow, 2008). Postmortem tissue can provide
a window into alterations in brain structure at a cellular and
molecular level, but deriving causal inferences from pathological
studies of neurodevelopmental or neurodegenerative diseases
has many challenges. Into this breach come iPSC-derived
neurons and glial cells from human patients.
iPSCs are adult pluripotent stem cells that are generated from
somatic cells by the introduction of reprogramming factors. Like
other pluripotent stem cells, iPSCs can be coaxed to differen-
tiate into neurons and glial cells, as well as other terminally differ-
entiated cell types, by exposure to a combination of growth
factors and cell culture conditions. Human iPSCs (hiPSCs) thus
make it possible to study human neurons, a previously inacces-
sible cell type, carrying the genetic information frompatients with
a specific mutation or a neuropsychiatric disease.
Because hiPSCs capture the genetic diversity of the patient,
they are well suited to study how specific sets of mutations
lead to disease, something that would be hard to replicate in
genetically engineered animals. Most neuropsychiatric disor-
ders, including autism, schizophrenia, and depression, have
a strong genetic component. However, though a single mutation
may cause a disease in rare cases, it is more common for
disease to arise from multiple genetic events. This is evident
from the fact that the mutations that have been identified for
neuropsychiatric diseases are not highly penetrant and are often
associated with multiple disorders, indicating that there is
a contribution from other genetic, epigenetic, or environmentalfactors (Geschwind, 2008; Vassos et al., 2010). hiPSCs thus
provide a clear advantage over animal models for studying the
effect of human genetic background on disease penetrance
and severity.
A further advantage of using hiPSC-derived neurons is that
they offer the only practical way of studying the development
and function of live human neurons. Rodents diverged from
humans almost 60 million years ago, and lower vertebrates
and invertebrates are even more distantly related. Therefore,
there are major differences in development and structure
between rodent and human brains (Clowry et al., 2010). Mice
are lissencephalic, whereas the human cortex has complicated
sulci and gyri. Rodents also have far less-developed prefrontal
and temporal cortices, whereas the prefrontal and temporal
cortex and other interconnected association areas compose
the majority of the human cortex. These regions are particularly
important in the context of complex neuropsychiatric diseases.
Human brain development is also quite different from the devel-
opment of the rodent brain both in terms of the timing and the
origin of cortical neurons. A significant amount of human neuro-
genesis occurs in the outer subventricular zone, an area that is
significantly reduced in rodents. Specific types of neurons
such as Von Economo neurons are found in humans and other
large mammals and not in rodents (Allman et al., 2011) and
may be key disease targets in dementia. In addition, neurons
from different species, even when closely related, have different
electrophysiological properties (Steffenhagen et al., 2011).
These gross differences suggest that there are underlying
molecular and cellular differences between humans and rodents
that could impact the validity of preclinical models, a supposition
that has been confirmed by genome-scale studies of transcrip-
tional networks. Given these differences, it is not surprising
that the therapies found to be effective in rodents are often not
effective in patients in the clinic (Dragunow, 2008).
The advantages of hiPSC-derived neurons and the prospect of
developing better preclinical models for neuropsychiatric
diseases led several groups to generate hiPSCs from patients
with genetic neurological disorders (Marchetto et al., 2010;
Park et al., 2008; Urbach et al., 2010). Early studies focused
largely on the generation of hiPSCs and their ability to generateCell 145, June 10, 2011 ª2011 Elsevier Inc. 831
neurons as a proof of principle. Only recently have a small
number of papers reported cellular phenotypes associated
with neuropsychiatric disease. This is significant because it
was not clear at first that hiPSCs would be useful for modeling
neuropsychiatric disorders, as many of these disorders are
thought to be due to defects in the development of neural circuits
that might not be picked up in cellular assays from reprog-
rammed somatic cells.
One of the earliest reports of a phenotype for a neurological
disease using iPSCs involved neural crest precursors from
patients with familial dysautonomia (Lee et al., 2009). This
disease is caused by a point mutation in the gene encoding
IKBKAP and leads to loss of autonomic and sensory neurons.
The authors generated iPSCs from a single patient with the
disease and directed the differentiation of these cells along the
neural crest lineage. They found defects in IKBKAP splicing,
changes in gene expression, and defects in cell migration in
patient cells that could be partially reversed by treatment with
the plant hormone kinetin. This paper provided a proof of prin-
ciple that iPSCs could be used to identify a cellular phenotype
associated with a neurological disease but did not provide addi-
tional insights into the pathogenesis of the disorder.
Cellular disease phenotypes were identified by two groups
studying iPSC-derived neurons from patients with Rett syn-
drome (Cheung et al., 2011;Marchetto et al., 2010), a neurodeve-
lopmental disorder that has been linked to mutations in the
gene encoding methyl-CpG-binding protein 2 (MECP2). Rett
syndrome neurons were found to have small cell bodies and
reduced numbers of synapses and retained an inactive X chro-
mosome as observed in patients. Some of these phenotypes
could be rescued by treatment with IGF-1 and large amounts
of gentamycin (Marchetto et al., 2010). These studies were
significant because they recapitulated observations that had
been made in mouse models of Rett syndrome, demonstrating
that phenotypes observed in vivo can be identified at a cellular
level in iPSC-derived human neurons and that cells developed
in culture largely confirm the phenotypes of cells that develop
in a mouse.
The most common mutation related to Parkinson’s disease
(PD) occurs in the gene encoding leucine-rich repeat kinase-2
(LRRK2). Nguyen et al. found that iPSC-derived dopaminergic
neurons from patients carrying this mutation had increased
expression of oxidative stress response genes and a-synuclein
protein (Nguyen et al., 2011). The mutant neurons were also
more sensitive to caspase-3 activation and cell death caused
by exposure to hydrogen peroxide, MG-132 (a proteasome
inhibitor), and 6-hydroxydopamine than control neurons. The
finding of increased susceptibility to stress in patient-derived
neurons provides insights into the pathogenesis of PD and
a potential basis for a cellular screen.
Tackling a complex disease with less well-defined genetic
determinants, Brennand et al. studied iPSC-derived neurons
from four patients with idiopathic forms of schizophrenia
(Brennand et al., 2011). Neurons from these patients had defects
in connectivity determined by an assay that used rabies virus
to label synaptically connected neurons, providing the first
report of a defect in neuronal connections in iPSC-derived neu-
rons from neuropsychiatric patients. The synaptic connectivity832 Cell 145, June 10, 2011 ª2011 Elsevier Inc.phenotype was reversed by one of the five commonly used anti-
psychotic drugs, although the mechanism underlying this defect
remains unclear. The rabies virus is transmitted retrogradely
from dendrites to axons, so it is not a measure of active
synapses, and neurons from schizophrenia patients did not
have any intrinsic defects in excitatory or inhibitory synaptic
input asmeasured electrophysiologically. The paper also reports
changes in gene expression in the patient cells that are consis-
tent with defects in cyclic AMP and WNT signaling. Extending
iPSC technology beyond monogenic diseases to the study of
complex genetic conditions could reveal common cellular
features among all patients with a particular diagnosis. However,
it remains to be formally addressed whether so few patient
samples from a complex disease such as schizophrenia with
iPSCs will yield generalizable results.
Though these early papers are promising, there are clearly
many issues that need to be resolved before iPSC-derived
cellular models can be usedmore widely. These include showing
reproducibility between lines from the same patient and between
different patients. In this regard, recent work comparing the
neural differentiation potential of 16 iPSC and six ESC lines in
two different laboratories (Boulting et al., 2011) represents
a key step in the right direction. Given the variability in cell lines
and new findings that iPSC lines may accumulate point muta-
tions or copy number variations (CNVs) in culture (Gore et al.,
2011; Hussein et al., 2011), it is also important to study more
iPSC lines in greater depth. Thus, it is remarkable that
genome-wide expression profiling has not been routinely
performed to understand variability in this process and the
cellular-molecular phenotypes from iPSC-derived neurons in
a more fine-grained manner. It is also not certain that epigenetic
susceptibility factors will be propagated in iPSCs derived from
patients, necessitating epigenetic profiling as well. Hopefully
such analysis, such as the recent comprehensive transcriptional
and epigenetic profiling in 20 iPSC and ESC lines (Bock et al.,
2011), will become more standard in the field so that transcrip-
tional influences on molecular and physiological relevant pheno-
types at a genome-wide level will be understood.
This highlights a major limitation of the current iPSC tech-
nology, namely the expensive and time-consuming nature of
the research. At the moment, each iPSC line is expensive and
takes months to generate and characterize. If we are to use
iPSC technology to study more diverse populations of patients,
we will need to invest in cell culture automation and develop
new approaches for making iPSC generation and characteriza-
tion more efficient and robust. Possible solutions to this problem
may emerge from new techniques for the direct generation of
neurons from fibroblasts (Vierbuchen et al., 2010). This tech-
nology may be faster than generation of neurons from iPSCs
but is currently inefficient in humans and has the disadvantage
that it does not mimic neuronal development. Thus, it may
miss phenotypes that occur during early development.
A second concern is that the methods for generating neurons
from iPSCs are still being developed and that the resulting pop-
ulations of neurons have not been well characterized. For
instance, the results of the early papers suggest that neurons
derived from hiPSCs and indeed from human embryonic stem
cells are not fully mature. This is apparent from the fact that
Figure 1. Niches Occupied by Various Experimental Approaches
Different models and approaches are complementary and will likely all need to
be pursued and integrated to achieve the level of mechanistic understanding
needed to develop new therapeutic approaches. Three axes are depicted,
increasing human relevance (Y), increasing molecular or mechanistic insight
(X), and increasing throughput (Z). The primate (most humanoid) systems are
labeled in blue, and the other vertebrate models are red. Studies in living
patients provide high human relevance but low molecular insights (e.g.,
functional imaging) and relatively low throughput. In contrast, mouse models
provide high levels of mechanistic or molecular insight at varying levels of
throughput and often unknown, but assumed, high human relevance. Zebra-
fish provide a higher-throughput model system, whereas nonhuman primates
are more relevant to humans but lower throughput and less genetically
manipulable. iPSCs promise high human relevance, likely high molecular and
mechanistic insight, and relatively low throughput currently, although there is
potential for higher throughput with automation and new methods. Primary
human neural cells derived from progenitors harvested from human embryonic
brain are higher throughput, but because they may not have all of the genetic
background characteristics of specific patients (in contrast with iPSC-derived
neurons), they may have slightly diminished human relevance and molecular
predictive power. Human postmortem tissue provides human relevance at
intermediate throughput but limited causality testing and hence lower mech-
anistic insight than the cell or animal models.only a fraction of the cells fire action potentials, many have
immature synapses, and most express markers of immature
neurons (Marchetto et al., 2010). Thus, phenotypes may be
limited to those that can be identified in young neurons. Further
optimization of culture methods and extensive electrophysiolog-
ical characterization of resulting neurons will be essential for
establishing useful in vitro models.
A related issue concerns the heterogeneity of the neuronal
cultures generated from hiPSCs. To draw convincing conclu-
sions about cellular phenotypes, it is essential to identify the cells
that are being generated and studied. Several methods of
identifying particular cell types are available, although they
have not yet been used in these first iPSC papers. One approach
is to use bacterial artificial chromosomes or viral reporter
genes to mark specific types of cells (Lee et al., 2009). These
approaches are laborious and suffer from a general lack of spec-
ificity, as the expression of a single gene is seldom enough to
identify a type of neuron or glial cell. An alternative is to use anti-
bodies to cell-specific markers to characterize different cell
types. This is complicated by a dearth of good antibodies for
human antigens and the difficulty in multiplexing more than a
few antibodies on a sample. An exciting new approach is to use
single-cell qPCR arrays to characterize gene expression profiles
in single cells (Nguyen et al., 2011). This method provides amore
comprehensive characterization of single neurons and could
potentially provide insights into specific cell fate and differentia-
tion phenotypes associated with specific diseases. The gene
expression pattern of a single cell can reflect its neurotransmitter
identity, cortical layer fate, and predicted projections and can
even predict probable location in the cortex. This technique
thus has the potential to reveal novel insights into the circuits
that are altered in specific disorders from in vitro cellular models.
The ultimate question, however, is whether hiPSC-derived
cells will be useful for identifying new therapeutic targets and
compounds. At present, hiPSC-derived neurons are difficult to
generate and are not sufficiently uniform for high-throughput
drug screening. On the other hand, these cells are valuable for
testing small numbers of compounds for efficacy and toxicity
in a specific patient or population of patients. This could be
a useful method for determining which drugs or drug combina-
tions are effective in humans or in specific patients. For this
approach to be valuable, however, it is essential to validate the
cellular phenotypes identified in neurons.
Validation is perhaps the largest unanswered question in
hiPSC disease models, especially for psychiatric diseases. In
other systems, like cardiomyocytes, it is considerably simpler
to show that a cellular phenotype in the lab accounts for defects
observed in patients (Yazawa et al., 2011). This is more chal-
lenging in neuropsychiatric diseases for which we have very little
information about neuroanatomical andmolecular phenotypes in
patients.
iPSC-derived neurons are derived from patients with genetic
neuropsychiatric disease and thus harbor the genetic variants
that underlie human disease susceptibility. On the other hand,
because they are immature and have not developed in a brain,
they may not reflect the major pathology of a specific disorder.
One avenue for validation is to compare the phenotypes identi-
fied in iPSC-derived neurons with those identified in postmortemsamples. Finding the same phenotypes in hiPSC-derived
neurons and in neurons in the intact brain would provide some
evidence that the cell culture model recapitulates disease-
specific aspects of brain development. However, postmortem
samples havemany limitations andmay not showneurodevelop-
mental phenotypes that are critical elements of the disease
process. Thus, the development of other modalities, such as
high-resolution human brain imaging to explore molecules and
circuits at high-resolution in vivo, would be of great value. The
hardest level of validation to achieve for most psychiatric
diseases is to show that a drug that treats the disease in patients
also reverses the phenotype in the model (predictive validity).
This is a tall order partly because most treatments for neuropsy-
chiatric disease target behavioral or cognitive symptoms whose
structural or physiological analogs at the cellular level are largely
unknown. In addition, there are few treatments available for most
neuropsychiatric disease, making predictive validation the hard-
est level to achieve at present.Cell 145, June 10, 2011 ª2011 Elsevier Inc. 833
These limitations highlight the fact that iPSC-derived models
are only one weapon in the arsenal of tools needed to under-
stand and treat neuropsychiatric disease. If we are going to
use models to advance treatments of human neuropsychiatric
disease, we must reach a systems-level understanding of
disease pathophysiology, which requires leveraging and inte-
grating multiple levels of analysis (Geschwind and Konopka,
2009). We have to integrate information derived from genetic
analysis, hiPSC-derived cells, animal models, and human
studies. Each level has to inform the other in a bidirectional
manner (Figure 1). iPSCs have the potential to fill a critical gap
in this multifaceted approach by providing live, functional human
CNS cells with the complex genetic backgrounds found in
patients. They thus provide an important bridge between studies
in animal models and assessment of human postmortem brain
and brain function in living patients.ACKNOWLEDGMENTS
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